# dnaJ Peptide for Relieving Rheumatoid Arthritis

> **NCT00000435** · PHASE2 · COMPLETED · sponsor: **National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)** · enrollment: 160 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** dnaJ peptide
- **DRUG:** None-placebo

## Key facts

- **NCT ID:** NCT00000435
- **Lead sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-09
- **Primary completion:** —
- **Final completion:** 2004-09
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2007-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000435, "dnaJ Peptide for Relieving Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00000435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*